

Carmela Coppola

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8590724/publications.pdf>

Version: 2024-02-01

30
papers

1,305
citations

279487

23
h-index

500791

28
g-index

30
all docs

30
docs citations

30
times ranked

2045
citing authors

#	ARTICLE	IF	CITATIONS
1	The Long Non-Coding RNA Prader Willi/Angelman Region RNA5 (PAR5) Is Downregulated in Anaplastic Thyroid Carcinomas Where It Acts as a Tumor Suppressor by Reducing EZH2 Activity. <i>Cancers</i> , 2020, 12, 235.	1.7	39
2	Management of QT Prolongation Induced by Anticancer Drugs. <i>Current Clinical Pathology</i> , 2019, , 123-132.	0.0	0
3	Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. <i>Cancer Treatment Reviews</i> , 2018, 63, 135-143.	3.4	56
4	Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity. <i>Nutrients</i> , 2018, 10, 1304.	1.7	62
5	Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production. <i>Frontiers in Physiology</i> , 2018, 9, 38.	1.3	36
6	Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2241-2250.	1.0	26
7	Intracardiac metastasis originated from chondrosarcoma. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 385-388.	0.6	4
8	Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6785-6794.	1.0	24
9	Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, e55-e63.	0.6	12
10	Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, e19-e26.	0.6	47
11	Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1124-1131.	1.4	46
12	Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 105.	1.2	17
13	Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. <i>European Journal of Heart Failure</i> , 2014, 16, 358-366.	2.9	76
14	Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells. <i>Protein Engineering, Design and Selection</i> , 2014, 27, 83-88.	1.0	16
15	The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. <i>European Journal of Heart Failure</i> , 2013, 15, 482-489.	2.9	61
16	Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. <i>European Journal of Heart Failure</i> , 2012, 14, 130-137.	2.9	77
17	Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 511-521.	1.1	43
18	Le alterazioni elettrocardiografiche espressione di cardiotossicit�. <i>Journal of Cardiovascular Echography</i> , 2011, 21, 55-59.	0.1	0

#	ARTICLE	IF	CITATIONS
19	Early Identification of Left Ventricular Dysfunction Induced by Trastuzumab. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2698-2699.	1.2	3
20	Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 861-868.	0.6	45
21	Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 292, H2935-H2943.	1.5	61
22	Aging exacerbates negative remodeling and impairs endothelial regeneration after balloon injury. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 287, H2850-H2860.	1.5	53
23	Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 286, H902-H908.	1.5	35
24	Physical Training Increases eNOS Vascular Expression and Activity and Reduces Restenosis After Balloon Angioplasty or Arterial Stenting in Rats. <i>Circulation Research</i> , 2002, 91, 1190-1197.	2.0	85
25	Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor Simvastatin Prevents Cardiac Hypertrophy Induced by Pressure Overload and Inhibits p21rasActivation. <i>Circulation</i> , 2002, 106, 2118-2124.	1.6	105
26	Rat carotid artery dilation by PTCA balloon catheter induces neointima formation in presence of IEL rupture. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 283, H760-H767.	1.5	46
27	Membrane-Bound Protein Kinase A Inhibits Smooth Muscle Cell Proliferation In Vitro and In Vivo by Amplifying cAMP-Protein Kinase A Signals. <i>Circulation Research</i> , 2001, 88, 319-324.	2.0	45
28	Effects of Balloon Injury on Neointimal Hyperplasia in Streptozotocin-Induced Diabetes and in Hyperinsulinemic Nondiabetic Pancreatic Islet-Transplanted Rats. <i>Circulation</i> , 2001, 103, 2980-2986.	1.6	104
29	A new rat model of small vessel stenting. <i>Basic Research in Cardiology</i> , 2000, 95, 179-185.	2.5	43
30	Gene Therapy for Restenosis after Balloon Angioplasty and Stenting. <i>Cardiology in Review</i> , 1999, 7, 324-331.	0.6	38